Retina Synthesis

147 Folgen

1. Genetic Basis of Geographic Atrophy Treatment

   Vom: 2.9.2021
2. Dr. Caroline Baumal with brolucizumab safety update.

   Vom: 16.8.2021
3. Augmented Reality in Retina

   Vom: 12.8.2021
4. Focus on Samuel Barone, MD, CMO with Gemini Therapeutics

   Vom: 12.7.2021
5. Protocol W with Dr. Raj Maturi

   Vom: 15.6.2021
6. Update on the PANORAMA Trial

   Vom: 3.6.2021
7. A New Treatment Paradigm for Diabetic Macular Edema

   Vom: 27.4.2021
8. Home OCT Monitoring of Anti-VEGF Therapy of Macular Neovascularization

   Vom: 15.4.2021
9. Early Diagnosis of Macular Neovascularization

   Vom: 6.4.2021
10. Dr. Diana Do Discusses Kodiak KS-301 for nAMD, DME and RVO

    Vom: 1.4.2021
11. Focus on Dr. David Boyer of Retina Vitreous Associates Adjunct Professor, Keck School of Medicine of USC

    Vom: 7.3.2021
12. Focus on Cedric Francois, MD, PhD, CEO, Apellis Pharmaceuticals

    Vom: 7.3.2021
13. Spotlight on Andrew Moshfeghi, MD, Associate Professor, USC Roski Eye Institute

    Vom: 7.3.2021
14. Dr. Charles Wykoff Interviews Karl Csaky MD, PhD Discussing Faricimab for DME and nAMD

    Vom: 7.3.2021
15. Focus on Arshad Khanani MD, MA Director of Clinical Services Sierra Eye Associates

    Vom: 7.3.2021
16. Dr. Carmen Puliafito Interviews Charles Wykoff MD, PhD: Faricimab Results in DME & nAMD

    Vom: 7.3.2021
17. Focus on Carl Regillo, MD, and PDS System

    Vom: 7.3.2021
18. Focus on Michael Goldstein , Chief Medical Officer at Ocular Therapeutix

    Vom: 6.3.2021
19. Spotlight on David Zacks, M.D., Ph.D. Co-Founder and Chief Science Officer at ONL Therapeutics

    Vom: 6.3.2021
20. Focus on Kourous Rezaei Chief Medical Officer at IVERIC bio

    Vom: 6.3.2021